Faculty of Pharmaceutical Sciences, Toho University, Miyama 2-2-1, Funabashi, Chiba 274-8510, Japan.
BMC Complement Altern Med. 2014 Nov 6;14:435. doi: 10.1186/1472-6882-14-435.
Diabetes complications include various symptoms such as diabetic neuropathy and cognitive disorders. Aldose reductase (AR) is the rate-limiting enzyme of the polyol pathway and is one of the causal factors of diabetes complications. In this study, the bioactivities of eight selected Kampo formulations that are currently in clinical use for diabetes complications were assessed using human AR (hAR) inhibitory activity as the primary parameter to explore the possibilities of novel clinical applications of these formulations in the treatment of diabetes complications.
The hAR inhibitory activities of four Kampo formulations that are clinically used for diabetic neuropathy, four Kampo formulations that are used for cognitive disorders, and a total of 21 component crude drugs were measured. Furthermore, the hAR inhibitory activity of Glycyrrhizae Radix preparata was measured to determine the effect of frying, which is one of the specific processing of Glycyrrhizae Radix. hAR inhibitory activity was determined by measuring the rate of decline in the absorbance of NAPH at 340 nm using 0.5 mM NADPH, 10 mM D,L-glyceraldehyde, and 3.6 mU/mL hAR in phosphate buffer solution (0.2 M, pH 6.2).
All of the Kampo formulations exhibited significant hAR inhibitory activity; Chotosan exhibited particularly strong activity. Among the 21 crude drugs tested, adequate inhibitory activities were found for the following, in descending order of activity: Glycyrrhizae Radix > Paeoniae Radix > Chrysanthemi Flos > Cinnamomi Cortex > Phellodendri Cortex > Uncariae Uncis cum Ramulus > Bupleuri Radix. Glycyrrhizae Radix preparata exhibited an inhibitory activity that was nearly identical to that of Glycyrrhizae Radix.
Despite their seemingly different treatment objectives, all of the Kampo formulations that are clinically used for diabetes complications demonstrated significant hAR inhibitory activity. This activity might underlie the characteristic multi-target effects of Kampo formulations. Although the overall effect of a Kampo formulation is certainly difficult to evaluate based on specific herbal medications or components, the approach as taken in this study might nonetheless contribute to further advancement in the development of new drugs via the review of proper usage and re-examination of the chemical compounds from a new perspective.
糖尿病并发症包括各种症状,如糖尿病神经病变和认知障碍。醛糖还原酶(AR)是多元醇途径的限速酶,也是糖尿病并发症的原因之一。在这项研究中,使用人醛糖还原酶(hAR)抑制活性作为主要参数,评估了八种目前临床用于糖尿病并发症的汉方药的生物活性,以探讨这些配方在治疗糖尿病并发症中的新的临床应用的可能性。
测量了四种临床用于治疗糖尿病神经病变的汉方药、四种用于治疗认知障碍的汉方药以及总共 21 种原料药的 hAR 抑制活性。此外,还测量了炙甘草的 hAR 抑制活性,以确定炙甘草的一种特殊炮制方法——炒的效果。hAR 抑制活性通过测量在磷酸盐缓冲液(0.2 M,pH 6.2)中,用 0.5 mM NADPH、10 mM D,L-甘油醛和 3.6 mU/mL hAR 使 NAPH 的吸光度在 340nm 处下降的速率来确定。
所有汉方药都表现出显著的 hAR 抑制活性;柴苓汤表现出特别强的活性。在所测试的 21 种原料药中,以下原料药的抑制活性依次为:甘草>白芍>菊花>肉桂>黄柏>钩藤>柴胡。炙甘草与甘草的抑制活性几乎相同。
尽管临床用于糖尿病并发症的汉方药的治疗目标看似不同,但它们都表现出显著的 hAR 抑制活性。这种活性可能是汉方药多靶点作用的特征。虽然基于特定的草药药物或成分评估汉方药的整体效果当然是困难的,但本研究中采用的方法可能会通过审查适当的用法和从新的角度重新检查化合物,为新药的开发做出进一步的贡献。